Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005945 · ClinicalTrials.gov registry record · Phase 3
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
A Phase 3 study of Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,054
- Enrollment target
- 20
- Study locations
NCT00005945 is a Phase 3 study of Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 3,054 participants, above the 474-participant average among 233 other Leukemia trials with a reported enrollment target (544% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00005945, a Phase 3 study of Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,054 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- Southern California Permanente Medical Group - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Children's Hospital Los Angeles - Los Angeles
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Children's Hospital Central California - Madera
- Children's Hospital and Research Center at Oakland - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
- Children's Hospital of Orange County - Orange
- Kaiser Permanente Medical Center - Sacramento - Sacramento
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Santa Barbara Cottage Hospital - Santa Barbara
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- General Robert Huyser Cancer Center at David Grant Medical Center - Travis Air Force Base
Colorado
- Children's Hospital Cancer Center - Denver
- Presbyterian - St. Luke's Medical Center - Denver
Arizona
- Phoenix Children's Hospital - Phoenix
Connecticut
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,054 participants |
| Start Date | 2000-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005945
The ClinicalTrials.gov registry entry for NCT00005945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,054 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 474-participant average among 233 other Leukemia trials with a reported enrollment target (544% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005945 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT00005945 about?
NCT00005945 is a clinical study titled "Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukem...
What is the current status of trial NCT00005945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,054 participants. The study started on 2000-06. Estimated completion is 2008-06.
What conditions does trial NCT00005945 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00005945?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), doxorubicin hydrochloride (DRUG), cytarabine (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005945?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005945 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.